参考文献/References:
[1] 严福华.《新型冠状病毒感染的肺炎诊疗方案(试行第五版)》影像部分的解读[J].诊断学理论与实践,2020,19(1):4-6.
[2] Chang D,Lin M,Wei L,et al.Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan,China[J].JAMA,2020,323(11):1092-1093.
[3] 许 湘,李 鹏,魏 香.基于新型冠状病毒s蛋白结构及入胞机制的抗体与药物研发[J].中国生物化学与分子生物学报,2021,37(1):1-10.
[4] Chan JFW,Yuan S,Kok KH,et al.A familial cluster of pneumonia associated with the 2019-nCoV coronavirus indicating person-to-person transmission:A study of a family cluster[J].The Lancet,2020,395(10223):514-523.
[5] Xin Z,Ke C,Jiawei Z,et al.Single-cell rna-seq data analysis on the receptor ace2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection[J].Frontiers of Medicine,2020,14(2):185-192.
[6] Li F.Structure,Function,and evolution of coronavirus spike proteins[J].Annu Rev Virol,2016,3(1):1954-1964.
[7] 任云霞,贺文婷,潘龙飞,等.新型冠状病毒肺炎35例临床特征及外周血T淋巴细胞亚群水平[J].陕西医学杂 志,2020,49(10):1207-1210.
[8] Merle NS,Noe R,Halbwachs-Mecarelli L,et al.Complement system part Ⅱ:Role in immunity[J].Frontiers in Immunology,2016,6(6):1207-1210.
[9] Ritis K,Doumas M,Mastellos D,et al.A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways[J].Journal of Immunology,2006,44(1):266-268.
[10] Taisheng L,Zhifeng Q,Linqi Z,et al.Significant changes of peripheral tlymphocyte subsets in patients with severe acute respiratory syndrome[J].The Journal of Infectious Diseases,2004,189(4):1092-1093.
[11] Jenny L,Noser D,Larsen JB,et al.MASP-1 of the complement system alters fibrinolytic behaviour of blood clots[J].Molecular Immunology,2019,114(7):1-9.
[12] Brown EW,Ravindran S,Patston PA.The reaction between plasmin and C1-inhibitor results in plasmin inhibition by the serpin mechanism[J].Blood Coagulation & Fibrinolysis An International Journal in Haemostasis & Thrombosis,2002,13(8):711-714.
[13] Cui S,Chen S,Li X,et al.Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia[J].Journal of Thrombosis and Haemostasis,2020,18(6):1421-1424.
[14] Arachchillage DRJ,Laffan M.Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia[J].Journal of Thrombosis and Haemostasis,2020,18(4):844-847.
[15] Wilk AJ,Rustagi A,Zhao NQ,et al.A single-cell atlas of the peripheral immune response in patients with severe COVID-19[J].Nature medicine,2020,26(7):1070-1076.
[16] 董陈颍,杨 鸿.新型冠状病毒引起的细胞因子风暴及中医药治疗[J].中华中医药学刊,2020,23(7):15-18.
[17] Tetsuya M,Shuetsu F,Daisuke I,et al.Inhibition of cell proliferation by sars-cov infection in vero E6 cells[J].Fems Immunology & Medical Microbiology,2006,34(2):236-243.
[18] Zhu N,Zhang D,Wang W,et al.A novel coronavirus from patients with pneumonia in China,2019[J].New England Journal of Medicine,2020,382(8):727-733.
[19] Shen B,Yi X,Sun Y,et al.Proteomic and metabolomic characterization of COVID-19 patient sera[J].Cell,2020,182(1):59-72.
[20] 卢洪洲.新型冠状病毒肺炎的药物治疗方案[J].上海医药,2020,41(1):52-53.
[21] Wang M,Cao R,Zhang L,et al.Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019-nCoV)in vitro[J].Cell Research,2020,30(3):1-3.
[22] 田 成,向 明.瑞德西韦与α-干扰素联用治疗新型冠状病毒肺炎的可行性分析[J].医药导报,2020,39(4):477-482.
[23] 平 易,陈东风.新型冠状病毒肺炎的抗病毒治疗进展[J].现代医药卫生,2020,36(20):3194-3199.
[24] Nan W,Sha B,Rui L,et al.Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV spike pseudotyped virus[J].Phytomedicine,2020,79:153333.
[25] 陈碧珊,陈吉生.托珠单抗在新型冠状病毒肺炎的应用研究探讨[J].今日药学,2020,30(4):225-228.
[26] 解立新,谢社玲.新型冠状病毒肺炎免疫失衡与免疫调节治疗[J].中华结核和呼吸杂志,2020,43(9):717-721.
[27] 张月丹,周 军,周曙俊.胸腺肽α1在治疗重症肺炎中的相关研究[J].中国民康医学,2013,25(4):24,71.
[28] Ma J,Wei K,Liu J,et al.Glycogen metabolism regulates macrophage-mediated acute inflammatory responses[J].Nature Communications,2020,11(1):1769-1781.
[29] 汪 婷,蒋政宇,万小健,等.冠状病毒肺炎细胞因子风暴及免疫调控治疗[J].第二军医大学学报,2020,41(8):818-823.
[30] Lamberts SWJ,Bruining HA,Jong FHD.Corticosteroid therapy in severe illness[J].New England Journal of Medicine,1997,337(18):1285-1292.
[31] Chen RC,Tang XP,Tan SY,et al.Treatment of severe acute respiratory syndrome with glucosteroids[J].Chest,2006,129(6):1441-1452.
[32] Wang Y,Chen X,Cao W,et al.Plasticity of mesenchymal stem cells in immunomodulation:Pathological and therapeutic implications[J].Nature Immunology,2014,15(11):1009-1016.
[33] 王 峰,殷中伟,蒋建刚,等.静注人免疫球蛋白治疗新型冠状病毒肺炎危重症的回顾性分析[J].中国医院药学杂志,2020,40(14):1505-1510.
[34] 徐 畅,张英驰,郝 莎,等.间充质干细胞治疗新冠肺炎的科学性和可行性探讨[J].中国科学:生命科学,2020,50(8):802-811.
[35] 杨晓明,侯继峰.康复期血浆应用于急性病毒性传染病现状及其治疗新型冠状病毒肺炎前景[J].中国生物制品学杂志,2020,33(3):241-245.
[36] 李 营,张树超,张少强,等.康复者血浆治疗新型冠状病毒肺炎疗效分析1例[J].临床输血与检验,2020,22(4):366-370.
相似文献/References:
[1]金 璞,任郭侠△,赵 琳.陕西省新型冠状病毒肺炎流行病学与时空分布情况分析[J].陕西医学杂志,2020,49(5):515.
JIN Pu,REN Guoxia,ZHAO Lin..Epidemiology and spatiotemporal distribution of COVID-19 in Shaanxi Province[J].,2020,49(5):515.
[2]王素娜,姚 娜,汪春付,等.新型冠状病毒肺炎39例临床特征分析*[J].陕西医学杂志,2020,49(6):643.[doi:DOI:10.3969/j.issn.10007377.2020.06.001]
WANG Suna,YAO Na,WANG Chunfu,et al.Epidemiological and clinical characteristics of COVID-19 in Shaanxi,China[J].,2020,49(5):643.[doi:DOI:10.3969/j.issn.10007377.2020.06.001]
[3]吕艳红,刘朵朵,李 佳.新型冠状病毒奥密克戎变异株感染轻型及无症状患者核酸转阴时间影响因素分析[J].陕西医学杂志,2022,51(12):1511.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.010]
[4]郑宏波,于 芳△,王一龙,等.陕西咸阳地区新型冠状病毒肺炎流行病学研究[J].陕西医学杂志,2020,49(4):387.
ZHENG Hongbo,YU Fang,WANG Yilong,et al.Epidemiological investigation of corona virus disease 2019 in Xianyang area[J].,2020,49(5):387.